Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is reporting third quarter earnings results on Tuesday 3rd November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.30 per share.
For the full year, analysts predict revenues of $ 486.54 million, while looking forward to income of $ 1.43 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 460.00 million ~ $ 500.00 million
Click Here For More Historical Outlooks Of Supernus Pharmaceuticals, Inc.
Previous Quarter Performance
Supernus Pharmaceuticals, Inc. unveiled income for the second quarter of $ 0.65 per share, from the revenue of $ 126.73 million. The quarterly earnings elevated 20.37 percent while revenues swell 24.07 percent compared with the same quarter last year.
Wall street analysts are predicting, SUPN to report 2Q20 income of $ 0.45 per share from revenue of $ 127.86 million. The bottom line results beat street analysts by $ 0.2 or 44.44 percent, at the same time, top line results fell short of analysts by $ 1.13 million or 0.88 percent.
Stock Performance
Shares of Supernus Pharmaceuticals, Inc. traded up $ 0.01 or 0.05 percent on Monday, reaching $ 18.37 with volume of 453.20 thousand shares. Supernus Pharmaceuticals, Inc. has traded high as $ 18.63 and has cracked $ 17.75 on the downward trend
The closing price of $ 18.37, representing a 39.94 % increase from the 52 week low of $ 13.12 and a 37.47 % decrease over the 52 week high of $ 29.36.
The company has a market capital of $ 967.44 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The companys product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy.
